Fragment designation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-19 and is reviewed periodically as new material appears.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
=== Works cited === Brand, Chad; Mitchell, Eric (2015). Holman Illustrated Bible Dictionary. B&H Publishing Group. ISBN 978-0-8054-9935-3. Cross, Frank Moore (1973). Canaanite Myth and Hebrew Epic. Cambridge, Massachusetts: Harvard University Press. ISBN 978-0-674-09176-4. LCCN 72076564. OCLC 185400934. Dever, William (2003). Who Were the Early Israelites and Where Did They Come From?. Eerdmans. ISBN 978-0-8028-0975-9. Archived from the original on 1 July 2023. Retrieved 14 August 2015. Dever, William G. (2005). Did God Have a Wife?: Archaeology and Folk Religion in Ancient Israel. Wm. B. Eerdmans. ISBN 978-0-8028-2852-1. Retrieved 7 February 2016. Faust, Avraham (2015). "The Emergence of Iron Age Israel: On Origins and Habitus". In Levy, Thomas E.; Schneider, Thomas; Propp, William H. C. (eds.). Israel's Exodus in Transdisciplinary Perspective: Text, Archaeology, Culture, and Geoscience. Springer. pp. 467–482. ISBN 978-3-319-04768-3. Archived from the original on 21 October 2021. Retrieved 31 March 2023. Goldenberg, David M. (11 April 2009). The Curse of Ham: Race and Slavery in Early Judaism, Christianity, and Islam. Princeton University Press. pp. 90–91. ISBN 978-1-4008-2854-8. OCLC 1162398032. Grabbe, Lester L. (2004). A History of the Jews and Judaism in the Second Temple Period. T&T Clark International. ISBN 978-0-567-04352-8. Archived from the original on 1 July 2023. Retrieved 14 August 2015. Grabbe, Lester L., ed. (2008). Israel in Transition: From Late Bronze II to Iron IIa (c. 1250–850 B.C.E.). T&T Clark International. ISBN 978-0-567-02726-9.
== History == In 1923 Louis Ruprecht, a graduate from Stevens Institute of Technology, founded Pulverizing Company with offices in New York City and a small machine shop in Elizabeth, New Jersey. The company focused its efforts in micronizing or size reduction of powder materials. The first machine patented was the Mikro-Pulverizer which accomplished powder size reduction by mechanically impacting material with the use of a hammer and screen. The business outgrew its facilities in Elizabeth and moved to Roswell Park in 1932. In ten more years the company had once more outgrown these facilities and moved to Summit, New Jersey where it currently resides. In May, 1942 the Summit location opened and was immediately contracted by the US Army and Navy to produce materials for World War II. From 1942 to 1945 the company produced parts for tanks, warships and airplanes. Over one million pounds of magnesium powder were produced for tracer bullets and flares. During this time the Summit location was heavily guarded. In 1954, Louis Ruprecht died and the company was sold to Metals Disintegration Company in Union, New Jersey. After a number of ownership changes, finally, in 1985 the company was sold to the Micron Powder Group and the name was changed to Hosokawa Micron Powder Systems. The company current operates in a 14,000 square foot facility in Summit, New Jersey.
Pharmacology: the study of the biochemical and physiological effects of drugs on human beings. Pharmacodynamics: the study of the cellular and molecular interactions of drugs with their receptors. Simply "What the drug does to the body" Pharmacokinetics: the study of the factors that control the concentration of drug at various sites in the body. Simply "What the body does to the drug" Pharmaceutical toxicology: the study of the harmful or toxic effects of drugs. Pharmacogenomics: the study of the inheritance of characteristic patterns of interaction between drugs and organisms. Pharmaceutical chemistry: the study of drug design to optimize pharmacokinetics and pharmacodynamics, and synthesis of new drug molecules (Medicinal Chemistry). Pharmaceutics: the study and design of drug formulation for optimum delivery, stability, pharmacokinetics, and patient acceptance. Pharmacognosy: the study of medicines derived from natural sources. As new discoveries advance and extend the pharmaceutical sciences, subspecialties continue to be added to this list. Importantly, as knowledge advances, boundaries between these specialty areas of pharmaceutical sciences are beginning to blur. Many fundamental concepts are common to all pharmaceutical sciences. These shared fundamental concepts further the understanding of their applicability to all aspects of pharmaceutical research and drug therapy.
Many of these conditions are far more common and more likely to be the source of necrotic wounds, even in areas where brown recluse spiders actually occur. The most important of these is methicillin-resistant Staphylococcus aureus (MRSA), a bacterium whose necrotic lesions are very similar to those induced by recluse bites, and which can be lethal if left untreated. Misdiagnosis of MRSA as spider bites is extremely common (nearly 30% of patients with MRSA reported that they initially suspected a spider bite), and can have fatal consequences. Reported cases of brown recluse bites occur primarily in Arkansas, Colorado, Kansas, Missouri, Nebraska, Oklahoma, and Texas. There have been many reports of brown recluse bites in California – though a few related species of spiders may be found there, none of the related spiders in California is known to bite humans. To date, the reports of bites from areas outside of the spider's native range have been either unverified or, if verified, the spiders have been moved to those locations by travelers or commerce.
==== Ionic selectivity and plasticity ==== Several groups reinvestigated the permeability properties of TPCs and their role in NAADP-induced Ca2+ release, and they agreed that TPCs are indeed permeable to Na+ but they could not necessarily recapitulate the Na+ selectivity shown in the 2012/13 studies. It was therefore initially proposed that TPCs may conduct both Ca2+ and Na+ (analogous to the NMDA receptor of the plasma membrane). As more studies were published, why some groups observe a Na+ selectivity while others see a mixed Na+/Ca2+ permeability was unclear until the important realization that the TPC2 ionic selectivity wholly depended on the activating ligand. Currents activated by PI(3,5)P2 were predominantly carried by Na+ whereas NAADP-activated currents showed an eight-fold increase in the Ca2+ permeability. This conveniently explained the discrepancies between groups as well as revealing that TPC2 is extraordinarily plastic in operating in different conductance modalities. Since then, it appears that TPC2 can be synergistically activated by co-application of NAADP and PI(3,5)P2, although the molecular mechanisms are unclear. Therefore, TPC2 can operate as either a Ca2+ or Na+ channel, depending on whether NAADP or lipid activate it.
Sources: en.wikipedia.org
== Awards and distinctions == 2025: Chevalier, Ordre national de la Légion d'honneur 2025: Engaged for the ocean award of Fondation de la mer 2024: Fellow, Association for the Sciences of Limnology and Oceanography 2023, Elected foreign member, Chinese Academy of Sciences 2020, Ruth Patrick Award, Association for the Sciences of Limnology and Oceanography 2018, Elected member, Academia Europaea 2014, Blaise Pascal Medal in Earth and Environmental Sciences, and elected member of the European Academy of Sciences 2012, Vladimir Vernadsky Medal, European Geosciences Union 2005, Union Service Award, European Geosciences Union 2002, Outstanding reviewer, Limnology & Oceanography 2001, Oceanography medal, Société d'océanographie de France
== Precision fermentation == Precision fermentation is an approach to manufacturing specific functional products which intends to minimise the production of unwanted by-products through the application of synthetic biology, particularly by generating synthetic "cell factories" with engineered genomes and metabolic pathways optimised to produce the desired compounds as efficiently as possible with the available resources. Precision fermentation of genetically modified microorganisms may be used to manufacture proteins needed for cell culture media, providing for serum-free cell culture media in the manufacturing process of cultured meat. A 2021 publication showed that photovoltaic-driven microbial protein production could use 10 times less land for an equivalent amount of protein compared to soybean cultivation. Some Food Regulatory Agencies such as the FDA do not require the labeling of precision fermented foods as GMO since they are produced by, but do not contain the genetically engineered organisms. It is unclear how regulation will be handled in EU markets, with some startups such as Formo and Those Vegan Cowboys forming the Food Fermentation Europe (FFE) alliance together with other alt-protein startups to seek regulatory approval.
The deportees were released on 19 December and allowed to travel to Cairo and then, with Jamal Husseini, to Beirut where a new Arab Higher Committee (or Higher National Committee) was established. Amin al-Husayni was not a member of the Arab delegation but the delegation was clearly acting under his direction. The London Conference commenced on 7 February 1939, but the Arab delegation refused to sit in the same room with the Jewish delegation present, and the conference broke up in March with no success. In May 1939, the British government presented its 1939 White Paper which was rejected by both sides. The White Paper had, in effect, repudiated the Balfour Declaration. According to Benny Morris, Amin al-Husayni "astonished" the other members of the Arab Higher Committee by turning down the White Paper. Al-Husayni turned the advantageous proposal down because "it did not place him at the helm of the future Palestinian state." The deportees were not allowed to return to Palestine until 1941. Amin Al-Husayni spent the war years in occupied Europe, actively collaborating with the Nazi leadership. Amin and Jamal al-Husayni were involved in the 1941 pro-Nazi Rashidi revolt in Iraq. Amin again evaded capture by Britain but Jamal was captured in 1941 and interned in Southern Rhodesia, where he was held until November 1945 when he was allowed to move to Cairo. Husayn al-Khalidi returned to Palestine in 1943. Jamal al-Husayni returned to British Palestine in February 1946 as an official of the new Arab Higher Committee, by then recognised by the Mandate administration.
==== Convergent evolution ==== Color change is widespread in ectotherms including anoles, frogs, mollusks, many fish, insects, and spiders. The mechanism behind this color change can be either morphological or physiological. Morphological change is the result of a change in the density of pigment containing cells and tends to change over longer periods of time. Physiological change, the kind observed in cephalopod lineages, is typically the result of the movement of pigment within the chromatophore, changing where different pigments are localized within the cell. This physiological change typically occurs on much shorter timescales compared to morphological change. Cephalopods have a rare form of physiological color change which utilizes neural control of muscles to change the morphology of their chromatophores. This neural control of chromatophores has evolved convergently in both cephalopods and teleosts fishes.
The S&P SmallCap 600 (S&P 600) stock market index, maintained by S&P Dow Jones Indices, comprises the common stocks of 600 small-cap, mostly American, companies. Although called the "S&P 600", the index contains 603 stocks because it includes two share classes of stock from three of its component companies (Central Garden & Pet Company, Clearway Energy and Under Armour). Stocks here are cross referenced with the following index funds to compose the list:
Sources: en.wikipedia.org
== Epidemiology == The current estimated global incidence annually is 20,000 to 50,000 people, though a large number of cases are believed to go unreported. Due to the limited habitats of ciguatoxin-producing microorganisms, ciguatera is common only in subtropical and tropical waters, particularly the Pacific and Caribbean, and usually is associated with fish caught in tropical reef waters. Exportation of reef fish, as well as tourism, often account for cases that develop in other regions. Ciguatoxin is found in over 400 species of reef fish. Avoiding consumption of all reef fish is the only sure way to avoid exposure. Imported fish served in restaurants may contain the toxin and produce illness which often goes unexplained by physicians unfamiliar with the symptoms of a tropical toxin. Ciguatoxin can also occur in farm-raised salmon. Furthermore, species substitution, labeling a reef fish as a non-reef fish at restaurants and retail, can complicate efforts by consumers to avoid ciguatera.
=== Hormones === Urine pregnancy test ― detects human chorionic gonadotropin in urine Urine cortisol ― used to investigate disorders of the adrenal glands Urine metanephrines ― used to help diagnose some rare tumours
Steel (with smaller carbon content than pig iron but more than wrought iron) was first produced in antiquity by using a bloomery. Blacksmiths in Luristan in western Persia were making good steel by 1000 BC. Then improved versions, Wootz steel by India and Damascus steel were developed around 300 BC and AD 500 respectively. These methods were specialized, and so steel did not become a major commodity until the 1850s. New methods of producing it by carburizing bars of iron in the cementation process were devised in the 17th century. In the Industrial Revolution, new methods of producing bar iron without charcoal were devised and these were later applied to produce steel. In the late 1850s, Henry Bessemer invented a new steelmaking process, involving blowing air through molten pig iron, to produce mild steel. This made steel much more economical, thereby leading to wrought iron no longer being produced in large quantities.
== External links == AccelrysPKA — Accelrys CHARMm based pKa calculation H++ — Poisson–Boltzmann based pKa calculations MCCE2 — Multi-Conformation Continuum Electrostatics (Version 2) Karlsberg+ — pKa computation with multiple pH adapted conformations PETIT — Proton and Electron TITration GMCT — Generalized Monte Carlo Titration DEPTH web server — Empirical calculation of pKa values using Residue Depth as a major feature
=== Secretome alters with exercise === A study examined the biopsies of a thigh skeletal muscle (vastus lateralis muscle) of eight 23-year old, originally sedentary, Caucasian males. Biopsies were taken both before and after a six-week long endurance exercise training program. The exercise consisted of riding a stationary bicycle for one hour, five days a week for six weeks. Of the 13,108 genes with detected expression in the muscle biopsies, 641 genes were upregulated after endurance training and 176 genes were downregulated. Of the 817 total altered genes, 531 were identified as being in the secretome by either or both of UniProt or ExoCarta, or else by studies investigating the secretome of muscle cells. Because many of the exercise-regulated genes are identified as secreted, this indicates that much of the effect of exercise has an endocrine rather than metabolic function. The main pathways found to be affected by secreted exercise-regulated proteins were related to cardiac, cognitive, kidney and platelet functions.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.